Company Psychemedics Corporation

Equities

PMD

US7443752057

Healthcare Facilities & Services

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Sector Medical & Diagnostic Laboratories

Delayed Nasdaq Other stock markets 01:51:27 2024-06-10 pm EDT			5-day change	1st Jan Change
2.29 ^USD	+1.78%		-3.78%	-22.64%

Mar. 28	Psychemedics Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 25	North American Morning Briefing : Tech in Focus on -2-	DJ

Psychemedics Corporation is a hair drug testing company. The Company provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The Company customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The Company markets its corporate drug testing services through its own sales force, distributors, and partners. It markets its home drug testing service, PDT-90, through the Internet.

Number of employees: 116

USD in Million	2022	Weight	2023	Weight	Delta
Testing 84.4 %	22	85.6 %	19	84.4 %	-13.64%
Shipping/Collection (Hair) 15.0 %	3	13.8 %	3	15.0 %	-4.60%
Other 0.5 %	0	0.6 %	0	0.5 %	-22.44%

USD in Million	2022	Weight	2023	Weight	Delta
United States 96.0 %	25	97.1 %	21	96.0 %	-13.44%
International 4.0 %	1	2.9 %	1	4.0 %	+20.66%

Managers	Title	Age	Since
Brian Hullinger CEO	Chief Executive Officer	56	23-08-16
Daniella Mehalik DFI	Director of Finance/CFO	34	Nov. 26
Shannon Shoemaker PRN	Corporate Officer/Principal	38	23-09-20
Patrick J. Kinney SEC	Corporate Secretary	-	-

Members of the board	Title	Age	Since
Peter Kamin BRD	Director/Board Member	62	22-08-11
Darius Nevin CHM	Chairman	66	22-08-11
Robyn Davis BRD	Director/Board Member	63	21-03-15
Andrew Reynolds BRD	Director/Board Member	55	22-04-03
Brian Hullinger CEO	Chief Executive Officer	56	23-08-16

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,474,000	4,487,967 ( 69.32 %)	668,000 ( 10.32 %)	69.32 %

Name	Equities	%	Valuation
Peter Kamin 11.16 %	647,737	11.16 %	2 M $
Powell Anderson Capital Partners 5.378 %	312,199	5.378 %	749 278 $
22NW LP 4.727 %	274,418	4.727 %	658 603 $
Renaissance Technologies LLC 4.476 %	259,863	4.476 %	623 671 $
Vanguard Group, Inc. (Subfiler) 4.328 %	251,283	4.328 %	603 079 $
Raymond Kubacki 4.250 %	246,737	4.250 %	592 169 $
RBF Capital LLC 2.448 %	142,142	2.448 %	341 141 $
BlackRock Institutional Trust Co. NA 1.307 %	75,874	1.307 %	182 098 $
Wedbush Securities, Inc. 0.8689 %	50,443	0.8689 %	121 063 $
Geode Capital Management LLC 0.6408 %	37,205	0.6408 %	89 292 $

Psychemedics Corp.

5220 Spring Valley Road Suite 230

75254, Dallas

http://www.psychemedics.com

Healthcare

Healthcare Services

Healthcare Providers & Services

Healthcare Facilities & Services

Medical & Diagnostic Laboratories

	1st Jan change	Capi.
PSYCHEMEDICS CORPORATION	-22.64%	13.06M
SONIC HEALTHCARE LIMITED	-22.13%	7.9B
RADNET, INC.	+76.63%	4.53B
DR. LAL PATHLABS LIMITED	+8.00%	2.78B
SYNLAB AG	-2.80%	2.64B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-50.41%	1.99B
NEOGENOMICS, INC.	-18.72%	1.66B
FLEURY S.A.	-20.29%	1.49B
METROPOLIS HEALTHCARE LIMITED	+19.61%	1.23B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-45.78%	1.1B

Medical & Diagnostic Laboratories